ORBIMED ADVISORS LLC 13D and 13G filings for Passage Bio, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-26 4:31 pm Sale | 2024-12-20 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 7,404,869 12.000% | -629,131 (-7.83%) | Filing |
| 2024-04-12 5:35 pm Unchanged | 2024-04-09 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 8,034,000 13.000% | 0 (Unchanged) | Filing |
| 2023-06-29 4:36 pm Purchase | 2023-06-27 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 8,034,000 14.700% | 1,192,577 (+17.43%) | Filing |
| 2022-05-05 4:56 pm Purchase | 2022-05-03 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 6,841,423 12.600% | 894,100 (+15.03%) | Filing |
| 2021-01-28 1:48 pm Unchanged | 2021-01-26 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 5,947,323 11.200% | 0 (Unchanged) | Filing |
| 2020-03-09 4:53 pm Purchase | 2020-03-03 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 5,947,323 13.500% | 5,947,323 (New Position) | Filing |